<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Exp Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Exp Hepatol</journal-id><journal-id journal-id-type="publisher-id">CEH</journal-id><journal-title-group><journal-title>Clinical and Experimental Hepatology</journal-title></journal-title-group><issn pub-type="ppub">2392-1099</issn><issn pub-type="epub">2449-8238</issn><publisher><publisher-name>Termedia Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29594196</article-id><article-id pub-id-type="pmc">5865908</article-id><article-id pub-id-type="publisher-id">31800</article-id><article-id pub-id-type="doi">10.5114/ceh.2018.73484</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Evaluation of serum interleukin-10 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shakiba</surname><given-names>Ebrahim</given-names></name><xref ref-type="aff" rid="aff0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Ramezani</surname><given-names>Mazaher</given-names></name><xref ref-type="aff" rid="aff0002">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Sadeghi</surname><given-names>Masoud</given-names></name><xref ref-type="aff" rid="aff0003">3</xref></contrib></contrib-group><aff id="aff0001">
<label>1</label>Department of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran</aff><aff id="aff0002">
<label>2</label>Molecular Pathology Research Center, Emam Reza University Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran</aff><aff id="aff0003">
<label>3</label>Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence</bold> Masoud Sadeghi, Medical BIology Research Center, Kermanshah University of Medical Sciences, 67145-1673 Kermanshah, Iran. phone: 00989185960644. e-mail: <email xlink:href="sadeghi_mbrc@yahoo.com">sadeghi_mbrc@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2018</year></pub-date><volume>4</volume><issue>1</issue><fpage>35</fpage><lpage>40</lpage><history><date date-type="received"><day>25</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>15</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2018 Clinical and Experimental Hepatology</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.</license-p></license></permissions><abstract><sec id="s1"><title>Aim of the study</title><p>This meta-analysis aimed to evaluate serum IL-10 levels in HCC patients.</p></sec><sec id="s2"><title>Material and methods</title><p>The three databases PubMed, Scopus and Web of Science were checked on July 2017 for assessment of IL-10 levels in hepatocellular carcinoma (HCC) patients compared with healthy controls in publications with an English abstract. A&#x000a0;random-effect meta-analysis was performed using mean difference (MD) and 95% confidence intervals (CIs). Also, publication bias was evaluated through funnel plot analysis with the Begg&#x02019;s and Egger&#x02019;s tests.</p></sec><sec id="s3"><title>Results</title><p>Out of 171 studies searched in the databases, nine studies were included in the meta-analysis. The pooled analysis with continuous data concluded that IL-10 level in the patients was significantly higher than the controls (MD = 6.96; 95% CI = 4.91-9.01; <italic>p</italic> &#x0003c; 0.00001), in the HCC patients was significantly higher than the cirrhotic patients (MD = 2.92; 95% CI = 0.72-5.12; <italic>p</italic> = 0.009), and was similar in the HCC patients compared with the patients with hepatitis (MD = 3.91; 95% CI = &#x02013;4.25-12.07; <italic>p</italic> = 0.35).</p></sec><sec id="s4"><title>Conclusion</title><p>The increased IL-10 levels in the HCC patients compared with the cirrhotic patients and the healthy controls may show a&#x000a0;significant role of this cytokine in the elevated risk of HCC, but the lack of significant difference in the levels between HCC and hepatitis makes it an unreliable tumor marker in the latter.</p></sec></abstract><kwd-group><kwd>interleukin-10</kwd><kwd>hepatocellular carcinoma</kwd><kwd>cirrhosis</kwd><kwd>hepatitis</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Hepatocellular carcinoma (HCC) is one of the major malignant diseases worldwide, ranking as the fifth most common cancer [<xref rid="cit0001" ref-type="bibr">1</xref>] with poor prognosis and a&#x000a0;low five-year survival rate [<xref rid="cit0002" ref-type="bibr">2</xref>] that often occurs in patients with chronic liver disease, due to hepatitis B virus (HBV) or hepatitis C virus (HCV) infection [<xref rid="cit0001" ref-type="bibr">1</xref>, <xref rid="cit0003" ref-type="bibr">3</xref>]. Cytokines play an important role in differentiation, maturation, and functional activation of immune cells [<xref rid="cit0004" ref-type="bibr">4</xref>]. Interleukin-10 (IL-10) is a&#x000a0;pleiotropic cytokine produced by macrophages, T-helper 2 (Th2) cells and B-lymphocytes, and can stimulate and suppress the immune response. This interleukin has been shown to inhibit various immune reactions [<xref rid="cit0005" ref-type="bibr">5</xref>]. Serum IL-10 level has been reported to be significantly increased in patients with chronic hepatitis C and may be related to hepatocarcinogenesis with suppression of immune surveillance [<xref rid="cit0006" ref-type="bibr">6</xref>]. Therefore, it has been proposed that IL-10 plays a&#x000a0;key role in the oncogenetic and metastatic ability of neoplasms [<xref rid="cit0007" ref-type="bibr">7</xref>]. An elevated level of IL-10 have been found in the plasma of patients with different histotypes of solid and hematopoietic tumors [<xref rid="cit0008" ref-type="bibr">8</xref>] and has an inhibitory effect on cancer immunosurveillance [<xref rid="cit0009" ref-type="bibr">9</xref>]. IL-10 has been assessed as a&#x000a0;marker for HCC to predict postoperative recurrence of HCC [<xref rid="cit0007" ref-type="bibr">7</xref>, <xref rid="cit0009" ref-type="bibr">9</xref>]; however, it has not yet been validated for clinical use [<xref rid="cit0007" ref-type="bibr">7</xref>]. The aim of this meta-analysis was to evaluate serum IL-10 levels in HCC patients in comparison with healthy controls as well as hepatitis and cirrhotic patients.</p></sec><sec sec-type="material|methods" id="sec2"><title>Material and methods</title><sec id="sec2.1"><title>Search strategies</title><p>We used the terms &#x02018;IL-10&#x02019;, &#x02018;interleukin-10&#x02019; combined with &#x02018;liver cancer&#x02019;, &#x02018;HCC&#x02019; and &#x02018;hepatocellular carcinoma &#x02018;in the three databases PubMed, Scopus and Web of Science in July 2017 for publications with an English abstract.</p></sec><sec id="sec2.2"><title>Study selection</title><p>One author (M.S.) searched the articles followed by the second author (M.R.) blinded to the first author. If there was any disagreement between the two authors, third author (E.S.) resolved the problem. All studies were searched for assessment of IL-10 levels in the HCC patients compared with the healthy controls, cirrhotic patients or patients with hepatitis. The inclusion criteria for the studies included: &#x00399;) studies reporting the mean or median IL-10 level in HCC patients compared with the healthy controls, cirrhotic patients or patients with hepatitis; &#x00406;&#x00406;) only studies with English-language abstract could be included; &#x00406;II) human studies; IV) HCC was confirmed histologically or based on biopsy or cytologic findings; V) a&#x000a0;blood sample of IL-10 was taken after overnight fasting. The exclusion criteria were: &#x00399;) the studies did not report the mean or median IL-10 level; &#x00399;&#x00399;) data from incomplete reports (not sufficient information), review studies and conference papers were not eligible for this study.</p></sec><sec id="sec2.3"><title>Data extraction</title><p>The relevant data extracted from every study were the name of the author, year of publication, country, and number/age/male (%) of the HCC, cirrhosis, hepatitis and healthy control groups. Level of IL-10 was determined by enzyme-linked immunosorbent assay.</p></sec><sec id="sec2.4"><title>Statistical analysis</title><p>A&#x000a0;random-effect meta-analysis was performed by Review Manager 5.3 (RevMan 5.3, The Cochrane Collaboration, Oxford, United Kingdom) using mean difference (MD) and 95% confidence intervals (CIs). Heterogeneity between the estimates was evaluated by the Q and I<sup>2</sup> statistic where for the Q statistic, heterogeneity was considered if <italic>p</italic> &#x0003c; 0.1 and <italic>p</italic>-value (2-sided) &#x0003c; 0.05 was considered statistically significant in this meta-analysis. In addition, publication bias was evaluated through funnel plot analysis with the Begg&#x02019;s and Egger&#x02019;s tests. If the data were presented using the standard error (SE), then the formula <inline-formula id="IFD1"><mml:math id="ILM1"><mml:mrow><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>S</mml:mi><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:msqrt><mml:mi>N</mml:mi></mml:msqrt></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula> was used to calculate standard deviation (SD). We used the formula for estimation of mean and SD if the study reported the median plus range [<xref rid="cit0010" ref-type="bibr">10</xref>]. The unit of measurement of IL-10 in this meta-analysis was pg/ml.</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><p>Out of 171 studies searched in the databases after removing duplicate and non-relevant studies, 29 studies were assessed for eligibility, of which 20 studies were excluded based on exclusion criteria. Therefore, nine studies were included in the meta-analysis (<xref ref-type="fig" rid="f0001">Fig. 1</xref>).</p><fig id="f0001" position="float"><label>Fig. 1</label><caption><p>Flowchart of the study</p></caption><graphic xlink:href="CEH-4-31800-g001"/></fig><p>The characteristics of the studies included in the meta-analysis are shown in <xref ref-type="table" rid="t0001">Table 1</xref>. Three studies were reported from Japan [<xref rid="cit0006" ref-type="bibr">6</xref>, <xref rid="cit0011" ref-type="bibr">11</xref>, <xref rid="cit0012" ref-type="bibr">12</xref>], one from Korea [<xref rid="cit0001" ref-type="bibr">1</xref>], one from Taiwan [<xref rid="cit0009" ref-type="bibr">9</xref>], one from China [<xref rid="cit0013" ref-type="bibr">13</xref>], and three from Egypt [<xref rid="cit0014" ref-type="bibr">14</xref>-<xref rid="cit0016" ref-type="bibr">16</xref>]. Altogether the studies included 373 HCC patients, 215 healthy controls, 132 cirrhotic patients and 92 patients with hepatitis. In a&#x000a0;majority of studies, age and sex were matched between groups. One study [<xref rid="cit0006" ref-type="bibr">6</xref>] showed the mean of IL-10 on a&#x000a0;graph from which we estimated it. Two studies [<xref rid="cit0012" ref-type="bibr">12</xref>, <xref rid="cit0014" ref-type="bibr">14</xref>] reported SE and two studies [<xref rid="cit0011" ref-type="bibr">11</xref>, <xref rid="cit0013" ref-type="bibr">13</xref>] reported median (range), which we changed to SD and mean &#x000b1; SD, respectively.</p><table-wrap id="t0001" position="float"><label>Table 1</label><caption><p>The characteristics of the studies included in meta-analysis (<italic>n</italic> = 9)</p></caption><table frame="hsides" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Study, year</th><th align="center" rowspan="1" colspan="1">Country</th><th align="center" rowspan="1" colspan="1">HCC patients (<italic>n</italic>/mean age, years/male %)</th><th align="center" rowspan="1" colspan="1">Healthy controls (<italic>n</italic>/mean age, years/male %)</th><th align="center" rowspan="1" colspan="1">LC (<italic>n</italic>/mean age, years/male %)</th><th align="center" rowspan="1" colspan="1">CH (<italic>n</italic>/mean age, years/male %)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Kakumo, 1997</td><td align="center" rowspan="1" colspan="1">Japan</td><td align="center" rowspan="1" colspan="1">11/64/81.8</td><td align="center" rowspan="1" colspan="1">11/45/63.6</td><td align="center" rowspan="1" colspan="1">22/61/72.7</td><td align="center" rowspan="1" colspan="1">28/54/71.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Chau, 2000</td><td align="center" rowspan="1" colspan="1">Taiwan</td><td align="center" rowspan="1" colspan="1">67/63.4/89.6</td><td align="center" rowspan="1" colspan="1">27/&#x02013;/&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Hattori, 2003</td><td align="center" rowspan="1" colspan="1">Japan</td><td align="center" rowspan="1" colspan="1">74/median: 65/73</td><td align="center" rowspan="1" colspan="1">44/matched/&#x02013;</td><td align="center" rowspan="1" colspan="1">32/matched/&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ayada, 2006</td><td align="center" rowspan="1" colspan="1">Japan</td><td align="center" rowspan="1" colspan="1">8/56/75</td><td align="center" rowspan="1" colspan="1">19/34/68.4</td><td align="center" rowspan="1" colspan="1">12/53/83.3</td><td align="center" rowspan="1" colspan="1">34/37/55.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Jang, 2012</td><td align="center" rowspan="1" colspan="1">Korea</td><td align="center" rowspan="1" colspan="1">110/58.6/71.8</td><td align="center" rowspan="1" colspan="1">24/&#x02013;/&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Wang, 2012</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">38/median: 53/82</td><td align="center" rowspan="1" colspan="1">30/median: 50/77</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Othman, 2013</td><td align="center" rowspan="1" colspan="1">Egypt</td><td align="center" rowspan="1" colspan="1">20/60.1/60</td><td align="center" rowspan="1" colspan="1">20/51.5/50</td><td align="center" rowspan="1" colspan="1">20/55.6/75</td><td align="center" rowspan="1" colspan="1">20/55.1/65</td></tr><tr><td align="left" rowspan="1" colspan="1">El-Emshaty, 2015</td><td align="center" rowspan="1" colspan="1">Egypt</td><td align="center" rowspan="1" colspan="1">15/57.1/86.7</td><td align="center" rowspan="1" colspan="1">10/35.6/70</td><td align="center" rowspan="1" colspan="1">16/46.1/75</td><td align="center" rowspan="1" colspan="1">10/35.8/90</td></tr><tr><td align="left" rowspan="1" colspan="1">Eltaher, 2016</td><td align="center" rowspan="1" colspan="1">Egypt</td><td align="center" rowspan="1" colspan="1">30/59/60</td><td align="center" rowspan="1" colspan="1">30/30/66.6</td><td align="center" rowspan="1" colspan="1">30/53/50</td><td align="center" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn><p>HCC &#x02013; hepatocellular carcinoma, LC &#x02013; liver cirrhosis, CH &#x02013; chronic hepatitis</p></fn></table-wrap-foot></table-wrap><sec id="sec3.1"><title>Meta-analysis</title><sec id="s3a1"><title>HCC patients versus healthy controls</title><p>
<xref ref-type="fig" rid="f0002">Figure 2</xref> shows a&#x000a0;forest plot of the random effect of serum IL-10 level in the HCC patients compared with the healthy controls. The pooled analysis with continuous data concluded that IL-10 level in the patients was significantly higher than the controls (MD = 6.96; 95% CI = 4.91-9.01; <italic>p</italic> &#x0003c; 0.00001) and I<sup>2</sup> = 89% (<italic>p</italic> &#x0003c; 0.00001).</p><fig id="f0002" position="float"><label>Fig. 2</label><caption><p>Forest plot of random effect of serum IL-10 level in hepatocellular carcinoma patients compared with healthy controls (<italic>n</italic> = 9)</p></caption><graphic xlink:href="CEH-4-31800-g002"/></fig></sec><sec id="s3a2"><title>HCC versus cirrhotic patients</title><p>
<xref ref-type="fig" rid="f0003">Figure 3</xref> shows a&#x000a0;forest plot of serum IL-10 level in the HCC patients compared with the cirrhotic patients. The pooled analysis showed that IL-10 level in the HCC patients was significantly higher than the cirrhotic patients (MD = 2.92; 95% CI = 0.72-5.12; <italic>p</italic> = 0.009) and I<sup>2</sup> = 89% (<italic>p</italic> &#x0003c; 0.00001).</p><fig id="f0003" position="float"><label>Fig. 3</label><caption><p>Forest plot of random effect of serum IL-10 level in hepatocellular carcinoma patients compared with cirrhotic patients (<italic>n</italic> = 6)</p></caption><graphic xlink:href="CEH-4-31800-g003"/></fig></sec><sec id="s3a3"><title>HCC patients versus patients with hepatitis</title><p>A&#x000a0;forest plot of serum IL-10 level in the HCC patients compared with the patients with hepatitis is shown in <xref ref-type="fig" rid="f0004">Figure 4</xref>. The pooled analysis showed that the level of this interleukin was similar in the two groups (MD = 3.91; 95% CI = &#x02013;4.25-12.07; <italic>p</italic> = 0.35) and I<sup>2</sup> = 99% (<italic>p</italic> &#x0003c; 0.00001).</p><fig id="f0004" position="float"><label>Fig. 4</label><caption><p>Forest plot of random effect of serum IL-10 level in hepatocellular carcinoma patients compared with patients with hepatitis (<italic>n</italic> = 4)</p></caption><graphic xlink:href="CEH-4-31800-g004"/></fig></sec></sec><sec id="sec3.2"><title>Publication bias</title><p>A&#x000a0;funnel plot for every analysis is shown in <xref ref-type="fig" rid="f0005">Figure 5</xref>. The results of the Begg&#x02019;s and Egger&#x02019;s tests revealed that no publication bias existed in terms of the comparison of serum IL-10 levels in the HCC and healthy control groups (<xref ref-type="fig" rid="f0005">Fig. 5A</xref>), the comparison of serum IL-10 levels in the HCC and cirrhosis groups (<xref ref-type="fig" rid="f0005">Fig. 5B</xref>), or the comparison of serum IL-10 levels in the HCC and hepatitis groups (<xref ref-type="fig" rid="f0005">Fig. 5C</xref>).</p><fig id="f0005" position="float"><label>Fig. 5</label><caption><p>Funnel plot of random effect of comparison of serum IL-10 levels in <bold>A)</bold> HCC patients and healthy controls, <bold>B)</bold> HCC and cirrhotic patients, <bold>C)</bold> HCC patients and patients with hepatitis</p></caption><graphic xlink:href="CEH-4-31800-g005"/></fig></sec></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>The meta-analysis showed that serum IL-10 level in the HCC patients was significantly higher than in the healthy controls and cirrhotic patients, but not the patients with hepatitis. IL-10 is known as a&#x000a0;pleiotropic cytokine with dual roles in the immune system, including immune suppression and immune stimulation [<xref rid="cit0017" ref-type="bibr">17</xref>]. Many studies have reported that serum IL-10 levels were higher in the HCC patients than in the healthy controls [<xref ref-type="fig" rid="f0001">1</xref>, <xref rid="cit0006" ref-type="bibr">6</xref>, <xref rid="cit0009" ref-type="bibr">9</xref>, <xref rid="cit0011" ref-type="bibr">11</xref>-<xref rid="cit0016" ref-type="bibr">16</xref>, <xref rid="cit0018" ref-type="bibr">18</xref>] and that a&#x000a0;higher IL-10 level was associated with worse prognosis [<xref rid="cit0019" ref-type="bibr">19</xref>]. Increased levels of IL-10 have been described as a&#x000a0;negative prognostic indicator for survival in patients with various types of cancer [<xref rid="cit0009" ref-type="bibr">9</xref>, <xref rid="cit0018" ref-type="bibr">18</xref>, <xref rid="cit0020" ref-type="bibr">20</xref>, <xref rid="cit0021" ref-type="bibr">21</xref>]. These findings confirm a&#x000a0;predominantly immunosuppressive role of IL-10 for circulating dendritic cells in patients with HCC, and thus may indicate novel aspects of tumor immune evasion [<xref rid="cit0018" ref-type="bibr">18</xref>]. IL-10 is an immune-suppressive cytokine and has been shown to inversely correlate with clinical outcome in patients with HCC [<xref rid="cit0009" ref-type="bibr">9</xref>, <xref rid="cit0022" ref-type="bibr">22</xref>]. Alpha-fetoprotein (AFP) is the single most important tumor marker for HCC. Although the detection of serum AFP level is well established in screening and diagnostic purposes for HCC, a&#x000a0;major shortcoming is that serum AFP is insensitive for early cancer detection [<xref rid="cit0023" ref-type="bibr">23</xref>]. IL-10 may help identify a&#x000a0;subset of HCC patients with a&#x000a0;low AFP level, and may serve as a&#x000a0;complementary tumor marker in these patients [<xref rid="cit0007" ref-type="bibr">7</xref>]. Patients with a&#x000a0;large (&#x0003e; 5 cm) HCC more often had significantly higher (&#x0003e; 20 ng/ml) AFP level and IL-10 expression [<xref rid="cit0007" ref-type="bibr">7</xref>].</p><p>Serum IL-10 levels have been observed to be significantly elevated in patients with type C chronic liver disease, and IL-10 may be related to the development of HCC [<xref rid="cit0006" ref-type="bibr">6</xref>]. Many studies have reported that serum IL-10 levels were higher in HCC patients than in patients with hepatitis [<xref rid="cit0006" ref-type="bibr">6</xref>, <xref rid="cit0014" ref-type="bibr">14</xref>, <xref rid="cit0015" ref-type="bibr">15</xref>], but one study had opposite results [<xref rid="cit0012" ref-type="bibr">12</xref>]. IL-10 was higher in the serum and the supernatants of cultured peripheral blood monocyte cells (PBMCs) from HBV-infected patients [<xref rid="cit0024" ref-type="bibr">24</xref>]. Serum IL-10 levels were reportedly higher in those with HBV compared with controls [<xref rid="cit0025" ref-type="bibr">25</xref>, <xref rid="cit0026" ref-type="bibr">26</xref>]. IL-10 plays key roles in the regulation of cellular immune response in HCV infection [<xref rid="cit0027" ref-type="bibr">27</xref>]. Some studies have found a&#x000a0;significant association between higher IL-10 serum levels and HCV infection when compared to a&#x000a0;healthy control group [<xref rid="cit0006" ref-type="bibr">6</xref>, <xref rid="cit0028" ref-type="bibr">28</xref>, <xref rid="cit0029" ref-type="bibr">29</xref>].</p><p>The current findings suggested that an elevated IL-10 level may be related to hepatic injury caused by cirrhotic processes rather than tumor load. The authors concluded that the IL-10 level offers additional prognostic value to the existing tumor staging systems [<xref rid="cit0030" ref-type="bibr">30</xref>]. Many studies have reported that serum IL-10 levels were higher in HCC patients than in cirrhotic patients [<xref rid="cit0006" ref-type="bibr">6</xref>, <xref rid="cit0011" ref-type="bibr">11</xref>, <xref rid="cit0014" ref-type="bibr">14</xref>-<xref rid="cit0016" ref-type="bibr">16</xref>], but one study had opposite results [<xref rid="cit0012" ref-type="bibr">12</xref>]. IL-10 was correlated with alanine transaminase (ALT) when analyzed in all the patients, but it was correlated with HBV-DNA in chronic hepatitis and in liver cirrhosis [<xref rid="cit0012" ref-type="bibr">12</xref>].</p></sec><sec id="sec5"><title>Limitations</title><p>1. Combination of liver disease with HCC in some studies. 2. No matching of mean age between groups in several studies. 3. Low number of patients and controls in several studies. 4. High heterogeneity between the studies in each analysis, but there was no bias. 5. Difference in consumption of alcohol in the studies. 6. Difference in the Child-Pugh score and AFP levels for HCC patients and cirrhosis and hepatitis groups between the studies. 7. Hepatitis virus relation to cirrhotic patients and vice versa in some studies.</p></sec><sec sec-type="conclusions" id="sec6"><title>Conclusions</title><p>The increased IL-10 levels in the HCC patients compared with the cirrhotic patients and the healthy controls may show a&#x000a0;significant role of this cytokine with elevated risk of HCC. In hepatitis the level is not significantly different from cancer, and thus it cannot be used as a tumor marker in hepatitis patients for evaluation of progression to HCC.</p></sec></body><back><ack><title>Acknowledgments</title><p>This article is part of a&#x000a0;research project (code: 95549) supported by a&#x000a0;grant from Kermanshah University of Medical Sciences Research Council.</p><sec sec-type="COI-statement"><title>Disclosure</title><p>Authors report no conflict of interest.</p></sec></ack><ref-list><title>References</title><ref id="cit0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>JW</given-names></name><name><surname>Oh</surname><given-names>BS</given-names></name><name><surname>Kwon</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma</article-title><source>Cytokine</source><year>2012</year><volume>60</volume><fpage>686</fpage><lpage>693</lpage><pub-id pub-id-type="pmid">22906998</pub-id></element-citation></ref><ref id="cit0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>F</given-names></name><name><surname>Tan</surname><given-names>H</given-names></name><etal/></person-group><article-title>Overrepresentation of IL-10-Expressing B Cells Suppresses Cytotoxic CD4+ T Cell Activity in HBV-Induced Hepatocellular Carcinoma</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><fpage>e0154815</fpage><pub-id pub-id-type="pmid">27136203</pub-id></element-citation></ref><ref id="cit0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Bisceglie</surname><given-names>AM</given-names></name></person-group><article-title>Hepatitis c and hepatocellular carcinoma</article-title><source>Hepatology</source><year>1997</year><volume>26</volume><fpage>34S</fpage><lpage>85S</lpage><pub-id pub-id-type="pmid">9305661</pub-id></element-citation></ref><ref id="cit0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>L</given-names></name><name><surname>Kung</surname><given-names>YJ</given-names></name><name><surname>Lin</surname><given-names>YJ</given-names></name><etal/></person-group><article-title>Th1 and Th2 cytokines are elevated in HCV-infected SVR(-) patients treated with interferon-&#x003b1;</article-title><source>Biochem Bioph Res Co</source><year>2009</year><volume>379</volume><fpage>855</fpage><lpage>860</lpage></element-citation></ref><ref id="cit0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naugler</surname><given-names>WE</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><article-title>The wolf in sheep&#x02019;s clothing: the role of interleukin-6 in immunity. Inflammation and cancer</article-title><source>Trends Mol Med</source><year>2008</year><volume>14</volume><fpage>109</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">18261959</pub-id></element-citation></ref><ref id="cit0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kakumu</surname><given-names>S</given-names></name><name><surname>Okumura</surname><given-names>A</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Serum levels of IL-10, IL-15 and soluble tumor necrosis factor-alpha (TNF-a) receptors in type C chronic liver disease</article-title><source>Clin Exp Immunol</source><year>1997</year><volume>109</volume><fpage>458</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">9328122</pub-id></element-citation></ref><ref id="cit0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsia</surname><given-names>CY</given-names></name><name><surname>Huo</surname><given-names>TI</given-names></name><name><surname>Chiang</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Evaluation of interleukin-6, interleukin-10 and human hepatocytegrowth factor as tumor markers for hepatocellular carcinoma</article-title><source>Eur J Surg Oncol</source><year>2007</year><volume>33</volume><fpage>208</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">17140760</pub-id></element-citation></ref><ref id="cit0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fortis</surname><given-names>C</given-names></name><name><surname>Foppoli</surname><given-names>M</given-names></name><name><surname>Gianotti</surname><given-names>L</given-names></name><etal/></person-group><article-title>Increased interleukin-10 serum levels in patients with solid tumours</article-title><source>Cancer Lett</source><year>1996</year><volume>104</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8640735</pub-id></element-citation></ref><ref id="cit0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chau</surname><given-names>GY</given-names></name><name><surname>Wu</surname><given-names>CW</given-names></name><name><surname>Lui</surname><given-names>WY</given-names></name><etal/></person-group><article-title>Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma</article-title><source>Ann Surg</source><year>2000</year><volume>231</volume><fpage>552</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">10749617</pub-id></element-citation></ref><ref id="cit0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hozo</surname><given-names>SP</given-names></name><name><surname>Djulbegovic</surname><given-names>B</given-names></name><name><surname>Hozo</surname><given-names>I</given-names></name></person-group><article-title>Estimating the mean and variance from the median, range, and the size of a sample</article-title><source>BMC Med Res Methodol</source><year>2005</year><volume>5</volume><fpage>13</fpage><pub-id pub-id-type="pmid">15840177</pub-id></element-citation></ref><ref id="cit0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattori</surname><given-names>E</given-names></name><name><surname>Okumoto</surname><given-names>K</given-names></name><name><surname>Adachi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma</article-title><source>Hepatol Res</source><year>2003</year><volume>27</volume><fpage>309</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">14662119</pub-id></element-citation></ref><ref id="cit0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayada</surname><given-names>M</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Okumura</surname><given-names>A</given-names></name><etal/></person-group><article-title>Alteration of serum cytokine balances among different phases of chronic hepatitis B virus infection</article-title><source>Hepatol Res</source><year>2006</year><volume>34</volume><fpage>214-221</fpage><pub-id pub-id-type="pmid">16469532</pub-id></element-citation></ref><ref id="cit0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XD</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Ji</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Decreased CD27 on B Lymphocytes in Patients with Primary Hepatocellular Carcinoma. Decreased CD27 on B lymphocytes in patients with primary hepatocellular carcinoma</article-title><source>J Int Med Res</source><year>2012</year><volume>40</volume><fpage>307</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">22429370</pub-id></element-citation></ref><ref id="cit0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Othman</surname><given-names>MS</given-names></name><name><surname>Aref</surname><given-names>AM</given-names></name><name><surname>Mohamed</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Serum Levels of Interleukin-6 and Interleukin-10 as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients</article-title><source>ISRN Hepatol</source><year>2013</year><volume>2013</volume><fpage>412317</fpage><pub-id pub-id-type="pmid">27335826</pub-id></element-citation></ref><ref id="cit0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Emshaty</surname><given-names>HM</given-names></name><name><surname>Nasif</surname><given-names>WA</given-names></name><name><surname>Mohamed</surname><given-names>IE</given-names></name></person-group><article-title>Serum Cytokine of IL-10 and IL-12 in Chronic Liver Disease: The Immune and Inflammatory Response</article-title><source>Dis Markers</source><year>2015</year><volume>2015</volume><fpage>707254</fpage><pub-id pub-id-type="pmid">26783377</pub-id></element-citation></ref><ref id="cit0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eltaher</surname><given-names>SM</given-names></name><name><surname>El-Gil</surname><given-names>R</given-names></name><name><surname>Fouad</surname><given-names>N</given-names></name><etal/></person-group><article-title>Evaluation of serum levels and significance of soluble CD40 ligand in screening patients with hepatitis C virus-related hepatocellular carcinoma</article-title><source>East Mediterr Health J</source><year>2016</year><volume>22</volume><fpage>603</fpage><lpage>610</lpage><pub-id pub-id-type="pmid">27834442</pub-id></element-citation></ref><ref id="cit0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mocellin</surname><given-names>S</given-names></name><name><surname>Panelli</surname><given-names>MC</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><etal/></person-group><article-title>The dual role of IL-10</article-title><source>Trends Immunol</source><year>2003</year><volume>24</volume><fpage>36</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">12495723</pub-id></element-citation></ref><ref id="cit0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beckebaum</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>7260</fpage><lpage>7209</lpage><pub-id pub-id-type="pmid">15534100</pub-id></element-citation></ref><ref id="cit0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0139598</fpage><pub-id pub-id-type="pmid">26440936</pub-id></element-citation></ref><ref id="cit0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>HD</given-names></name><name><surname>Park</surname><given-names>BL</given-names></name><name><surname>Kim</surname><given-names>LH</given-names></name><etal/></person-group><article-title>Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma</article-title><source>Hum Mol Genet</source><year>2003</year><volume>12</volume><fpage>901</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">12668613</pub-id></element-citation></ref><ref id="cit0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salgado</surname><given-names>R</given-names></name><name><surname>Junius</surname><given-names>S</given-names></name><name><surname>Benoy</surname><given-names>I</given-names></name><etal/></person-group><article-title>Circulating interleukin-6 predicts survival in patients with metastatic breast cancer</article-title><source>Int J Cancer</source><year>2003</year><volume>103</volume><fpage>642</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">12494472</pub-id></element-citation></ref><ref id="cit0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Achyut</surname><given-names>BR</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name></person-group><article-title>Transforming growth factorbeta in the gastrointestinal and hepatic tumor microenvironment</article-title><source>Gastroenterology</source><year>2011</year><volume>141</volume><fpage>1167</fpage><lpage>1178</lpage><pub-id pub-id-type="pmid">21839702</pub-id></element-citation></ref><ref id="cit0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zakhary</surname><given-names>NI</given-names></name><name><surname>El-Merzabani</surname><given-names>MM</given-names></name><name><surname>El-Sawi</surname><given-names>NM</given-names></name><etal/></person-group><article-title>Impact of different biochemical markers in serum of patients with benign and malignant liver diseases</article-title><source>J Adv Res</source><year>2011</year><volume>2</volume><fpage>49</fpage><lpage>55</lpage></element-citation></ref><ref id="cit0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>HF</given-names></name><name><surname>Feng</surname><given-names>CQ</given-names></name></person-group><article-title>Activation-induced cell death in peripheral blood mononuclear cells (PBMCs) from patients with chronic hepatitis B may be related to abnormal production of interleukin 12 and 10</article-title><source>J Viral Hepat</source><year>2001</year><volume>8</volume><fpage>30</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">11155149</pub-id></element-citation></ref><ref id="cit0025"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tulek</surname><given-names>N</given-names></name><name><surname>Saglam</surname><given-names>SK</given-names></name><name><surname>Saglam</surname><given-names>M</given-names></name><etal/></person-group><article-title>Soluble interleukin-2 receptor and interleukin-10 levels in patients with chronic hepatitis B infection</article-title><source>Hepatogastroenterology</source><year>2000</year><volume>47</volume><fpage>828</fpage><lpage>831</lpage><pub-id pub-id-type="pmid">10919040</pub-id></element-citation></ref><ref id="cit0026"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>FS</given-names></name><name><surname>Xing</surname><given-names>LH</given-names></name><name><surname>Liu</surname><given-names>MX</given-names></name><etal/></person-group><article-title>Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection</article-title><source>World J Gastroenterol</source><year>2001</year><volume>7</volume><fpage>537</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">11819824</pub-id></element-citation></ref><ref id="cit0027"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aroucha</surname><given-names>DC</given-names></name><name><surname>do Carmo</surname><given-names>RF</given-names></name><name><surname>Moura</surname><given-names>P</given-names></name><etal/></person-group><article-title>High tumor necrosis factor-&#x003b1;/interleukin-10 ratio is associated with hepatocellular carcinoma in patients with chronic hepatitis C</article-title><source>Cytokine</source><year>2013</year><volume>62</volume><fpage>421</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">23602201</pub-id></element-citation></ref><ref id="cit0028"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akcam</surname><given-names>FZ</given-names></name><name><surname>Tigli</surname><given-names>A</given-names></name><name><surname>Kaya</surname><given-names>O</given-names></name><etal/></person-group><article-title>Cytokine levels and histopathology in chronic hepatitis B and chronic hepatitis C</article-title><source>J Interferon Cytokine Res</source><year>2012</year><volume>32</volume><fpage>570</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">23067363</pub-id></element-citation></ref><ref id="cit0029"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abayli</surname><given-names>B</given-names></name><name><surname>Canatarog&#x002d8;lu</surname><given-names>A</given-names></name><name><surname>Akkiz</surname><given-names>H</given-names></name></person-group><article-title>Serum profile of T helper 1 and T helper 2 cytokines in patients with chronic hepatitis C virus infection</article-title><source>Turk J Gastroenterol</source><year>2003</year><volume>14</volume><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">14593531</pub-id></element-citation></ref><ref id="cit0030"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>SL</given-names></name><name><surname>Mo</surname><given-names>FK</given-names></name><name><surname>Wong</surname><given-names>CS</given-names></name><etal/></person-group><article-title>A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma</article-title><source>Cancer</source><year>2012</year><volume>118</volume><fpage>3984</fpage><lpage>3992</lpage><pub-id pub-id-type="pmid">22180222</pub-id></element-citation></ref></ref-list></back></article>